Table 3.
Antiretroviral therapy (ART) characteristics for PWH with T-cell, NK/T-cell, and AIDS-defining B-cell lymphomas in NA-ACCORD (N = 717)
| Features | TCL and NK/TCL (n = 52) | BL (n = 101) | PCNSL (n = 64) | DLBCL (n = 500) | P * |
|---|---|---|---|---|---|
| ART therapy† | |||||
| Yes, no. (%) | 48 (92) | 96 (95) | 61 (95) | 479 (96) | .61‡ |
| Different categories of ART, no. (%) | |||||
| Standard (NNRTI, PI, and NRTI)§ | 14 (27) | 12 (12) | 20 (31) | 124 (25) | .02ǁ |
| Standard (3-4 NRTIs)§ | 4 (8) | 2 (2) | 2 (3) | 29 (6) | .29 |
| Other (2 or fewer drugs)¶ | 42 (81) | 86 (85) | 56 (90) | 449 (90) | .18 |
| INSTI-based# | 13 (25) | 35 (35) | 6 (9) | 142 (28) | .004ǁ |
| Unknown | 0 | 0 | 0 | 1 (<1) | |
| Median length of time since NA-ACCORD enrollment (y) | 5.2 (2.2-8.8) | 5.9 (2.8-9.6) | 3.3 (1.5-5.5) | 5.6 (2.5-9.5) | <.001ǁ |
| Duration of ART (y), median (IQR) | 6.5 (3.3-9.2) | 7.6 (2.5-12.8) | 3.9 (2.1-8.2) | 7.9 (3.6-13.8) | <.001ǁ |
| Duration of ART before lymphoma diagnosis (y), median (IQR) | 3.9 (1.3-6.5) | 2.9 (0.7-8.0) | 2.5 (0.9-5.5) | 4.8 (1.2-9.4) | .01ǁ |
| Duration of ART after lymphoma diagnosis (y), median (IQR) | 1.4 (0.2-4.8) | 3.2 (0.3-7.3) | 0.3 (0.1-1.2) | 1.3 (0.3-6.1) | <.001ǁ |
P values for the comparison between patients in different lymphoma groups (Burkitt’s, PCNSL, DLBCL, and TCL and NK/TCLs) were calculated using Kruskal-Wallis and χ2 tests for non-normally distributed continuous variables and categorical variables, respectively.
ART therapy here is defined as patients being on at least 1 class of antiretroviral medications during their cohort enrollment period.
P values based on Fisher’s exact test because of some small cell counts.
Patient was considered on standard ART if they fell into 1 of the following 2 categories on 1 occasion or more during their cohort enrollment period: (1) were on at least 1 NNRTI, 1 PI, and 1 NRTI triple combination or (2) were on at least 3 NRTIs.
Bonferroni adjusted P values for pairwise comparison: PI-based ART: Burkitt’s vs TCL and NK/TCL, PCNSL, DLBCL: .03, .008, <.001, NNRTI-based ART: PCNSL vs Burkitt’s, DLBCL: .02, .003, Non-standard regimen ART: Burkitt’s vs PCNSL, DLBCL: .02, .046, Median duration of time in NA-ACCORD cohort: PCNSL vs Burkitt’s, DLBCL: <.001, <.001, Median duration of ART: PCNSL vs Burkitt’s, DLBCL: .048, <.001, Duration of ART before lymphoma diagnosis: PCNSL vs DLBCL: .02, duration of ART after lymphoma diagnosis: PCNSL vs Burkitt’s, DLBCL: <.001, <.001.
Patients were considered on other ART if they were on 2 or less drugs during their cohort enrollment period.
#Patients were considered on INSTI-based ART if 1 of the ART drugs was an INSTI during their cohort enrollment period. It is to be noted that, for example, if a patient was on 1 INSTI and 1 PI, they were included in both INSTI- and PI-based categories. During the cohort enrollment period, if a patient was on an INSTI, PI, or NNRTI drug more than once after a disruption, this was captured more than once in the categories specified, resulting in percentage greater than 100% when combined.